Nass

Ilan Nass from Taktical Digital Joins Forbes Agency Council

Retrieved on: 
Monday, October 9, 2023
Billboard, Bark, Advertising, Council, Nass, Craigslist, IPO, Software as a service, Care.com, Sales, Western Ghats Ecology Expert Panel, Manifest

NEW YORK, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Forbes Agency Council, an exclusive approval-only assembly for leading minds in public relations, media strategy, creative, and advertising sectors, welcomes a new esteemed member.

Key Points: 
  • Ilan Nass, founder and Chief Revenue Officer of Taktical Digital, has joined the Forbes Agency Council.
  • Taktical Digital is a performance marketing agency known for its innovative approach to combining brand and performance marketing strategies into a unified service known as 'Brandformance'.
  • Ilan Nass, founder and Chief Revenue Officer of Taktical Digital, has joined the Forbes Agency Council.
  • As a member of the Forbes Agency Council, Nass will have the opportunity to collaborate with other leaders in the field.

Ilan Nass from Taktical Digital Joins Forbes Agency Council

Retrieved on: 
Monday, October 9, 2023
Billboard, Bark, Advertising, Council, Nass, Craigslist, IPO, Software as a service, Care.com, Sales, Western Ghats Ecology Expert Panel, Manifest

NEW YORK, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Forbes Agency Council, an exclusive approval-only assembly for leading minds in public relations, media strategy, creative, and advertising sectors, welcomes a new esteemed member.

Key Points: 
  • Ilan Nass, founder and Chief Revenue Officer of Taktical Digital, has joined the Forbes Agency Council.
  • Taktical Digital is a performance marketing agency known for its innovative approach to combining brand and performance marketing strategies into a unified service known as 'Brandformance'.
  • Ilan Nass, founder and Chief Revenue Officer of Taktical Digital, has joined the Forbes Agency Council.
  • As a member of the Forbes Agency Council, Nass will have the opportunity to collaborate with other leaders in the field.

Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science

Retrieved on: 
Wednesday, May 24, 2023
Software, Research, Professional Services, Pharmaceutical, Oncology, Technology, Health Technology, Data Analytics, Clinical Trials, Science, Biotechnology, Health, European Medicines Agency, Monoclonal antibody, Probability, Data science, Nass, Neoplasm, COVID-19, Clinical trial, Cancer, Lung cancer, Messenger, Lung, Bone marrow, EMA, Hematological Cancer Research Investment and Education Act, CAR, Incidence, Hospital, GDP, Patient, EBP US, Composite, Growth, Pharmaceutical industry, Medical imaging

Diversity and inclusion of Black/African American and Hispanic patient populations in oncology clinical trials lag behind trials in all other top therapeutic areas.

Key Points: 
  • Diversity and inclusion of Black/African American and Hispanic patient populations in oncology clinical trials lag behind trials in all other top therapeutic areas.
  • “Global oncology continues to discover, develop and deliver important novel treatments that benefit more patients,” says Murray Aitken, Executive Director, the IQVIA Institute for Human Data Science.
  • There is a growing interest for bispecific antibodies, including six compounds marketed globally for oncology and many in development for rare hematological cancers.
  • Cancer patient access: The global numbers of treated patients have increased annually at an average 5% over the past five years.

Data I/O to Participate in the Electric Vehicle & Auto Tech Virtual Conference Presented by Maxim Group on Thursday, March 30, at 11:00 A.M. ET

Retrieved on: 
Thursday, March 23, 2023
Technology, General Automotive, Mobile, Wireless, Wearables, Mobile Technology, Automotive, Other Technology, IOT (Internet of Things), Networks, Internet, Hardware, Electronic Design Automation, Data Management, Security, Consumer Electronics, Embedded, IR, Interview, Maxim, Internet of things, Original equipment manufacturer, Electric vehicle, ICS, Data I/O, Car, Ambrose, Data, Host, Nass, Conference, Cryptocurrency

In addition to the presentation, Anthony Ambrose, Data I/O President and CEO, will be available for 1:1 meetings with institutional investors.

Key Points: 
  • In addition to the presentation, Anthony Ambrose, Data I/O President and CEO, will be available for 1:1 meetings with institutional investors.
  • According to Maxim Group, ongoing adoption of electric vehicles, more technology in automobiles, and lighter and more efficient batteries can create opportunities for companies in many sectors.
  • Executives involved in different parts of the electric vehicle and auto tech markets will discuss future opportunities and sector changes during the Maxim conference.
  • “I am excited to present at the Maxim Electric Vehicle & Auto Tech conference,” said Mr. Ambrose.

Global Clinical Trial Activity Remained Resilient in 2022 Despite The Continued Pandemic, Says IQVIA Institute

Retrieved on: 
Tuesday, March 14, 2023
COVID-19, Research, Clinical Trials, Professional Services, Biotechnology, DEI (Diversity, Equity and Inclusion), Health, Pharmaceutical, Science, Enablers (band), Data science, Clinical trial, Endocrinology, Drug, COVID, Initial public offering, Neurology, Patient, R, FDA, Vaccine, Therapy, Ecosystem, Nass, Pharmaceutical industry

In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021.

Key Points: 
  • In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021.
  • The report also found that clinical development productivity – a composite metric of success rates, clinical trial complexity and trial duration – increased dramatically in 2022, reversing a 10-year downward trend.
  • The global R&D ecosystem demonstrated impressive resilience during the continued pandemic with a relatively high level of clinical trial activity.
  • Clinical development productivity: The Clinical Development Productivity Index — a composite metric of success rates, clinical trial complexity and trial duration — rebounded in 2022, reversing a 10-year downward trend.

Global Biosimulation Market Research Report 2022: Analysis & Forecasts 2018-2021 & 2022-2028 by Component (Software, Service), & Application (Drug Discovery, Pre-Clinical, Clinical) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Health Technology, Contract research organization, Medication, Virtual reality, Drug discovery, Drug development, Component, Artificial intelligence, Probability, USD, Nass, Software, Safety, Computer simulation, Medical device, Pharmaceutical industry, Biosimulation

The "Global Biosimulation Market (2022 Edition) - Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biosimulation Market (2022 Edition) - Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.
  • Biosimulation drug discovery offers numerous opportunities for error elimination through computer simulation, which can improve drug performance and accuracy.
  • The report analyses the Biosimulation Market by End-User (Academic & Government Research Institutes, Pharmaceutical & Biotech Companies, Contract Research Organization, Regulatory Authorities).
  • The Global Biosimulation Market has been analysed by countries (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, China, Japan, India).

Global Biosimulation Market Report 2022-2028: A $3+ Billion Market in 2021 - Focus on United States, Canada, Mexico, Germany, United Kingdom, France, Italy, China, Japan, India

Retrieved on: 
Friday, December 23, 2022
USD, Virtual reality, Component, Drug discovery, Drug development, Contract research organization, Probability, Safety, Nass, Medication, Software, Computer simulation, Artificial intelligence, Medical device, Pharmaceutical industry, Biosimulation

Global Biosimulation Market was valued at USD 3011.50 Million in the year 2021.

Key Points: 
  • Global Biosimulation Market was valued at USD 3011.50 Million in the year 2021.
  • Biosimulation drug discovery offers numerous opportunities for error elimination through computer simulation, which can improve drug performance and accuracy.
  • The report analyses the Biosimulation Market by End-User (Academic & Government Research Institutes, Pharmaceutical & Biotech Companies, Contract Research Organization, Regulatory Authorities).
  • The Global Biosimulation Market has been analysed by countries (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, China, Japan, India).

Codashop Fan Art Fest launches October 8, featuring art from Genshin Impact, the blockbuster open-world action RPG

Retrieved on: 
Thursday, October 6, 2022
RSVP, IGN, Venmo, PST, Tears, Family, Nass, Twitter, Music, Partnership, Friends, Javits Center, FC Avanhard Kramatorsk, GLOBE, Creativity, RPG, Video game, Nightclub, Video game console, Themis, Instagram, Coda, Genshin Impact

Participants will be competing for prizes including Codashop vouchers for Genshin Impact Genesis Crystals and an exciting cash grand prize.

Key Points: 
  • Participants will be competing for prizes including Codashop vouchers for Genshin Impact Genesis Crystals and an exciting cash grand prize.
  • Game players and enthusiasts in New York City on October 8, 2022, can kick off the Codashop Fan Art Fest with a Genshin Impact art gallery experience, hosted by Coda.
  • In a true celebration of creativity and community, the Codashop Fan Art Fest will welcome Genshin Impact art of all sorts, from original digital and traditional art to original cosplay photography.
  • The cross-platform blockbuster hit Genshin Impact launched in September 2020 as a free-to-play open-world action RPG.

Tanya Nass Promoted to Vice President of People and Culture at ARC

Retrieved on: 
Wednesday, September 28, 2022
Other Transport, Air, Consulting, Transport, Professional Services, Other Travel, Transportation, Data Analytics, Travel, Other Professional Services, Culture, Senior Professional Baseball Association, Air travel, Human, Politics, Acquisition, Growth, Industry, SPHR, Environment, Government, Certification, Travel, Nass, George Mason University, CEO, Solution, Data, Leadership, ARC, Management

Airlines Reporting Corp. (ARC) today announced the promotion of Tanya Nass to vice president of people and culture, a new role within the ARC executive team.

Key Points: 
  • Airlines Reporting Corp. (ARC) today announced the promotion of Tanya Nass to vice president of people and culture, a new role within the ARC executive team.
  • Nass will oversee the human resources team, which includes internal communications and facilities across ARCs three main offices.
  • In her new position, Nass will lead the overall strategic direction of the people-related programs at ARC to help foster an environment and culture where all employees can flourish.
  • ARC accelerates the growth of global air travel by delivering forward-looking travel data, flexible distribution services and other innovative industry solutions.

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Retrieved on: 
Thursday, May 5, 2022
Drug development, Assistant professor, Prevalence, Fatty liver disease, Degenerative disease, Human, Risk, Hospital, Administration, New Enterprise Associates, Massachusetts General Hospital, GH, SEC, CEO, Veni, vidi, vici, Woman, NASDAQ, Bilirubin, Private Securities Litigation Reform Act, Patient, Fibrosis, FDA, Letter, Incidence, Uncertainty, Pandemic, Disease, NASH, Nass, Liver, Hypothalamus, Body composition, NEA, Optimism, Population, IND, Physician, Growth hormone, Liver disease, Non-alcoholic fatty liver disease, MD, Growth, Man, LUMO, Department, Orphan, GLOBE, UCB, Therapy, Lipolysis, Adult, Biological activity, Harvard Medical School, Pharmaceutical industry, Dietary supplement, Public relations, Lumos, NAFLD, EU, Science

Lumos Pharma is honored to partner with Dr. Dichtel and Massachusetts General Hospital to evaluate LUM-201 in NAFLD, commented Rick Hawkins, CEO and Chairman of Lumos Pharma.

Key Points: 
  • Lumos Pharma is honored to partner with Dr. Dichtel and Massachusetts General Hospital to evaluate LUM-201 in NAFLD, commented Rick Hawkins, CEO and Chairman of Lumos Pharma.
  • Nonalcoholic fatty liver disease is estimated to be prevalent in approximately 25% of adults worldwide.
  • This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adults with NAFLD.
  • The trial will evaluate a dose of 25 mg/day of LUM-201 in 10 men and women with NAFLD.